Enhance MD vs EverSlim
One bills every four weeks; the other puts the visit inside the price.
Enhance MD
Editorial
$184/mo
Enhance MD advertises $212 a month for compounded semaglutide on a twelve-month plan, delivered every four weeks, which is thirteen fills a calendar year and $230 a month. The low-dose tirzepatide plan bills $169 twelve times against a forty-eight-week term, or $184 a calendar month. Labs, the consultation and two-day shipping are described as included, and the semaglutide rate is stated as flat at all doses.
Pick it for: Readers who want the shorter refill interval and accept the extra fill
EverSlim
Editorial
$113/mo
EverSlim prices compounded semaglutide at a flat $113 a month and compounded tirzepatide at a flat $136, with the medication, the provider visit and shipping described as included in both. It reaches fifty states and the District of Columbia. No prepay ladder is published, so nothing has to be bought in advance to reach either rate.
Pick it for: Readers who want the visit priced in and a calendar month that is a month
Our verdict
Enhance MD charges $184 on a four-week cycle, which is thirteen bills a year rather than twelve. EverSlim charges $113 and states the consultation sits inside it. The cadence and the inclusions move in opposite directions.
What actually separates them
Enhance MD and EverSlim state different things about published price. Everything else they publish, they publish the same way.
Enhance MD costs $71 more than EverSlim — 63% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,356 at EverSlim against $2,208 at Enhance MD — a difference of $852.
| Enhance MD | EverSlim | |
|---|---|---|
| Published price | $184/mo | $113/mo |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.